Kawkab Scientific Bureau Pharmaceutical Import Profile — Iraq (DGFT 2022–2026)

Name: Kawkab Scientific Bureau Pharmaceutical Import Records from India — 3 Products, $3.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kawkab Scientific Bureau — Pharmaceutical Importer Profile (2026) | 3 Products, $3.9M Trade | TransData Nexus

Kawkab Scientific Bureau

Pharmaceutical Importer · Iraq · Cardiovascular Focus · $3.9M Total Trade · DGFT Verified

Kawkab Scientific Bureau is a pharmaceutical importer based in Iraq with a total trade value of $3.9M across 3 products in 3 therapeutic categories. Based on 107 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Kawkab Scientific Bureau sources from 2 verified Indian suppliers, with Micro Labs Limited accounting for 65.8% of imports.

Kawkab Scientific Bureau — Import Portfolio & Supplier Network

Kawkab Scientific Bureau import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Kawkab Scientific Bureau?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Micro Labs Limited	$27.6M	729	65.8%
Ajanta Pharma Limited	$14.3M	1,599	34.2%

Kawkab Scientific Bureau sources from 2 verified Indian suppliers across .

What Formulations Does Kawkab Scientific Bureau Import?

Formulation	Value	Ships
Pulmoxyl 500 (amoxycillin capsules BP	$411.2K	9
Pulmoxyl 500 (amoxicillin capsules BP	$203.2K	5
Bactoclav 625 (amoxycillin 500MG +	$200.0K	4
Supixime-100 dry syrup(cefixime for	$200.0K	4
Supixime 100 dry syrup cefixime for oral suspension USP 100MG 60 ML qty 98010 00 fac inv	$200.0K	4
Supixime 100 dry syrup cefixime for oralsuspension USP 100MG 60 ML qty 98184 00 fac	$150.0K	3
Avas 20 (atorvastatin 20MG tablets) Pack(3x10`s) (qty-102048.000	$150.0K	3
Avas-40 (atorvastatin tablets 40MG )pack3x10`s,qty 102349.000 fac inv no	$150.0K	3
Pulmoxyl 500 (amoxycillin capsules BP 500MG Pack 10x10`s,qty	$150.0K	3
Cefex 500 ( (cefalexin capsules 500MG BP) ) ( 10x10s ) ( qty- 39682.000	$150.0K	3
Cefex 500, (cefalexin capsules 500 MG BP) Pack (10x10`s ),(qty-48357.000	$150.0K	3
Avas-20 (atorvastain tablets 20MG ) pack3x10`s,qty	$150.0K	3
Pulmoxyl 500 (amoxycillin capsules BP 500MG ) Pack 10x10`s,qty	$150.0K	3
Pulmoxyl 500 (amoxycillin capsules BP 500MG) Pack 10x10`s,qty	$150.0K	3
Cefex 500(cefalexin capsules BP 500MG ,Pack 10x10`s,qty	$150.0K	3

Kawkab Scientific Bureau imports 1,033 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Valsartan	Cardiovascular	$2.4M	78	1.2%	14
2	Cefixime	Advanced Antibiotics	$1.2M	24	0.7%	11
3	Vildagliptin	Advanced Diabetes Medications	$247.4K	5	1.5%	11

Kawkab Scientific Bureau imports 3 pharmaceutical products across 3 categories into Iraq totaling $3.9M.

Kawkab Scientific Bureau — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Kawkab Scientific Bureau is a prominent pharmaceutical importer and distributor based in Baghdad, Iraq. Established in 1992, the company has grown to become one of the top five fastest-growing local pharmaceutical distribution companies in the country, securing a significant market share. Its operations encompass the importation, storage, and distribution of pharmaceutical products, including medicines, cosmetics, and medical devices, throughout Iraq.

The company's mission is to provide high-quality healthcare products at affordable prices, thereby improving accessibility to medicine for the Iraqi population. Guided by the philosophy that the health of the people is the wealth of the nation, Kawkab Scientific Bureau is committed to delivering on this commitment every single day.

2Distribution Network

Kawkab Scientific Bureau operates an extensive distribution network covering the entire Iraqi market, including major cities such as Erbil, Baghdad, Basra, Karbala, Tikrit, Sulaymaniyah, Duhok, Mosul, and Kirkuk. The company has invested in state-of-the-art warehouses with a capacity of 25,000 pallets, ensuring efficient storage and distribution of pharmaceutical products. These facilities comply with European and US-FDA guidelines of Good Distribution Practice (GDP), reflecting the company's commitment to maintaining high-quality standards in its operations.

3Industry Role

Kawkab Scientific Bureau plays a pivotal role in Iraq's pharmaceutical supply chain as a primary wholesaler and distributor. By importing a diverse range of pharmaceutical products and ensuring their availability across the country, the company serves as a critical link between international manufacturers and local healthcare providers. Its extensive distribution network and adherence to international quality standards position it as a key player in the Iraqi pharmaceutical market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Kawkab Scientific Bureau

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Kawkab Scientific Bureau's sourcing strategy exhibits a high degree of concentration, with its top three products—Valsartan, Cefixime, and Vildagliptin—accounting for 100% of its imports from India. This singular focus on a limited product range suggests a strategic choice to specialize in specific therapeutic areas, potentially allowing for deeper market penetration and expertise. However, this concentration also introduces risks associated with dependency on a narrow product portfolio, such as vulnerability to supply chain disruptions or changes in market demand for these specific medications. The company's reliance on two primary suppliers—Micro Labs Limited and Ajanta Pharma Limited—further underscores this concentration. While such focused partnerships can lead to favorable terms and streamlined operations, they also necessitate robust contingency planning to mitigate potential risks.

2Supply Chain Resilience

The resilience of Kawkab Scientific Bureau's supply chain is closely tied to its partnerships with Micro Labs Limited and Ajanta Pharma Limited. Both suppliers are established entities in the pharmaceutical industry, known for their adherence to international quality standards. This alignment ensures that the imported products meet the regulatory requirements of the Iraqi Ministry of Health. However, the company's limited supplier base may expose it to risks related to supply chain disruptions, such as production delays or geopolitical issues affecting trade routes. To enhance resilience, Kawkab Scientific Bureau may consider diversifying its supplier base and exploring alternative sourcing options.

Importing Pharmaceuticals into Iraq — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Iraq

1Regulatory Authority & Framework

The Iraqi pharmaceutical sector is regulated by the Iraq Drug Regulatory Authority (IDRA), which operates under the Ministry of Health. IDRA oversees various aspects of pharmaceutical regulation, including marketing authorization, pricing oversight, pharmacovigilance, inspections, import permissions, and promotion rules. The regulatory framework ensures that all pharmaceutical products, whether domestically produced or imported, meet the required safety, efficacy, and quality standards. Marketing authorizations are typically time-limited, commonly for five years, and are renewable with updated data. Generics follow an abbreviated, bioequivalence-driven route, while biologics and biosimilars require comparability packages.

2Import Licensing & GMP

Import licensing in Iraq is managed by the Ministry of Health, which requires all pharmaceutical products to be registered and approved before they can be marketed. This process involves submitting evidence of Good Manufacturing Practice (GMP) compliance, ensuring that imported products meet international quality standards. The Ministry of Health's Technical Affairs Directorate oversees the registration process, which includes verifying the safety, efficacy, and quality of pharmaceutical products. GMP certificates from recognized authorities, such as the European Medicines Agency (EMA) or the World Health Organization (WHO), are typically accepted, facilitating the importation of high-quality pharmaceutical products into Iraq.

Kawkab Scientific Bureau — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Kawkab Scientific Bureau's focus on importing specific therapeutic categories—Cardiovascular, Advanced Antibiotics, and Advanced Diabetes Medications—aligns with the prevalent health concerns in Iraq. The high import values for Valsartan and Cefixime indicate a significant demand for cardiovascular and antibiotic treatments, respectively. The inclusion of Vildagliptin in the product portfolio suggests a strategic response to the growing prevalence of diabetes in the region. By concentrating on these therapeutic areas, Kawkab Scientific Bureau aims to address critical healthcare needs and establish a strong presence in these segments of the Iraqi pharmaceutical market.

2Sourcing Profile

Kawkab Scientific Bureau's sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on specific therapeutic areas. The company's reliance on two primary suppliers—Micro Labs Limited and Ajanta Pharma Limited—indicates a preference for established manufacturers known for their adherence to international quality standards. This approach ensures that the imported products meet the regulatory requirements of the Iraqi Ministry of Health and align with the company's quality assurance policies.

3Market Positioning

Seller's Guide — How to Become a Supplier to Kawkab Scientific Bureau

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For new Indian suppliers, there is a realistic opportunity to partner with Kawkab Scientific Bureau by aligning with its specific product needs and quality standards. The company's concentrated sourcing strategy suggests that it is open to establishing strong partnerships with reliable suppliers who can meet its requirements. However, potential suppliers should be prepared to navigate the regulatory complexities of the Iraqi market and demonstrate compliance with the standards set by the Iraqi Ministry of Health.

2Requirements & Qualifications

Indian exporters seeking to supply Kawkab Scientific Bureau must ensure that their products are registered with the Iraqi Ministry of Health and comply with the country's pharmaceutical regulations. This includes obtaining the necessary import licenses and providing evidence of Good Manufacturing Practice (GMP) compliance. Additionally, products must meet the labeling requirements set by the Iraqi authorities, including the inclusion of electronic labels with QR codes for verification. Adhering to these standards is essential for gaining approval and establishing a successful partnership with Kawkab Scientific Bureau.

3How to Approach

Frequently Asked Questions — Kawkab Scientific Bureau

What products does Kawkab Scientific Bureau import from India?

Kawkab Scientific Bureau imports 3 pharmaceutical products across 3 categories. Top imports: Valsartan ($2.4M), Cefixime ($1.2M), Vildagliptin ($247.4K).

Who supplies pharmaceuticals to Kawkab Scientific Bureau from India?

Kawkab Scientific Bureau sources from 2 verified Indian suppliers. The primary supplier is Micro Labs Limited (65.8% of imports, $27.6M).

What is Kawkab Scientific Bureau's total pharmaceutical import value?

Kawkab Scientific Bureau's total pharmaceutical import value from India is $3.9M, based on 107 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Kawkab Scientific Bureau focus on?

Kawkab Scientific Bureau imports across 3 categories. The largest: Cardiovascular (62.5%), Advanced Antibiotics (31.1%), Advanced Diabetes Medications (6.4%).

Get Full Kawkab Scientific Bureau Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.